AcelRx Pharmaceuticals Inc (ACRX): Long-Term Growth With Biotech Innovators

Page 2 of 2

With increased stake, Neptune Technologies & Bioressources-Ord (NASDAQ:NEPT) will benefit from the progress of Acasti’s clinical trials. Acasti is focusing on a Phase II clinical trial to evaluate the effect of different daily doses of CaPre. The drug treats patients with high triglycerides. The results from the trials will lead to submission of an Investigational New Drug Filing for initiation of the Phase III trial of Capre.

Conclusion

All three biotechnology companies are progressing with clinical trials and focusing on product development. AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)’s Zalviso should overcome the problems associated with PCA IV and improve patient satisfaction. Moreover, AcelRx’s public offering will provide capital for its product development and clinical trials. Sarepta Therapeutics Inc (NASDAQ:SRPT)’s Eteplirsen’s good efficacy and safety profile indicates early FDA approval, and Phase I initiation for treatment of Marburg virus infection will drive revenue in the long run. Neptune’s Sherbrooke facility reconstruction and progress with its subsidiary, Acasti’s, clinical trial provide better prospects.

Madhukar Dubey has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

The article Long-Term Growth With Biotech Innovators originally appeared on Fool.com.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2